NCT06979076尚未招募1 期
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
MingSight Pharmaceuticals, Inc0 个研究点目标入组 12 人开始时间: 2026年7月1日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 12
- 主要终点
- The occurrence of AEs and SAEs, with abnormal laboratory tests results, abnormal physical examination findings, abnormal vital signs, and abnormal ECG readings
研究概览
简要总结
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older.
- •Diagnosis of CLL or SLL:
- •History of histologically documented CLL or SLL that meets iwCLL diagnostic criteria according to the 2018 guidelines, and
- •Indication for treatment as defined by the 2018 iwCLL guidelines, or the need for disease reduction prior to allogeneic transplantation.-
排除标准
- •Current transformation of CLL/SLL non-Hodgkin lymphoma or Hodgkin lymphoma.
- •Active and uncontrolled autoimmune cytopenia(s).
研究组 & 干预措施
MS-553, dose schedule 2 (DS2)
Experimental
干预措施: MS-553, DS2 (Drug)
MS-553, dose schedule 1 (DS1)
Experimental
干预措施: MS-553, DS1 (Drug)
结局指标
主要结局
The occurrence of AEs and SAEs, with abnormal laboratory tests results, abnormal physical examination findings, abnormal vital signs, and abnormal ECG readings
时间窗: Through study completion, an average of 2 years
次要结局
未报告次要终点
研究者
相似试验
终止
1 期
A Study Of The Selective PKC-β Inhibitor MS- 553Small Lymphocytic LymphomaAggressive LymphomaChronic Lymphocytic LeukemiaNCT03492125MingSight Pharmaceuticals, Inc60
Unknown
1 期
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaRelapsed or Refractory B Cell Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaWaldenstrom's MacroglobulinemiaMantle Zone Lymphoma Refractory/RecurrentFollicle Centre Lymphoma DiffuseDiffuse Large B Cell LymphomaNCT02981745Centaurus Biopharma Co., Ltd.200
进行中（未招募）
2 期
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Primary Biliary Cholangitis (PBC)NCT05896124Cascade Pharmaceuticals, Inc75
进行中（未招募）
1 期
Treatment of patients with cutaneous T-Zell LymphomEUCTR2014-000924-11-DERuprecht-Karls-University Heidelberg, Medical Faculty Mannheim represented by the chancellor25
已完成
2 期
Therapeutic exploratory study of KCB-1B for patients with tibial shaft fractureTibial shaft fractureJPRN-UMIN000000847Kaken Pharmaceutical Co.,Ltd.90